Venclexta — Net revenues
AbbVie Venclexta — Net revenues increased by 8.5% to $770M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.8%, from $665M to $770M. Over 4 years (FY 2021 to FY 2025), Venclexta — Net revenues shows an upward trend with a 11.3% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market penetration, successful clinical adoption, or expanded indications for the therapy, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross sales of a specific oncology pharmaceutical product, adjusted for returns, allowa...
Peer comparison
Comparable to product-specific net revenue disclosures for oncology or specialty pharmaceutical assets at peer biopharmaceutical companies.
abbv_segment_venclexta_net_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $435M | $492M | $488M | $473M | $505M | $515M | $516M | $538M | $571M | $590M | $589M | $614M | $637M | $677M | $655M | $665M | $691M | $726M | $710M | $770M |
| QoQ Change | — | +13.1% | -0.8% | -3.1% | +6.8% | +2.0% | +0.2% | +4.3% | +6.1% | +3.3% | -0.2% | +4.2% | +3.7% | +6.3% | -3.2% | +1.5% | +3.9% | +5.1% | -2.2% | +8.5% |
| YoY Change | — | — | — | — | +16.1% | +4.7% | +5.7% | +13.7% | +13.1% | +14.6% | +14.1% | +14.1% | +11.6% | +14.7% | +11.2% | +8.3% | +8.5% | +7.2% | +8.4% | +15.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's venclexta — net revenues?
- AbbVie (ABBV) reported venclexta — net revenues of $770M in Q1 2026.
- How has AbbVie's venclexta — net revenues changed year-over-year?
- AbbVie's venclexta — net revenues increased by 15.8% year-over-year, from $665M to $770M.
- What is the long-term trend for AbbVie's venclexta — net revenues?
- Over 4 years (2021 to 2025), AbbVie's venclexta — net revenues has grown at a 11.3% compound annual growth rate (CAGR), from $1.82B to $2.79B.
- What does venclexta — net revenues mean?
- The total net sales generated by a specific oncology drug product line.